ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2026
From aggregate structure to disease trajectory: the role of the proteostasis network.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are characterized by the accumulation of a small number of misfolded proteins, yet they differ markedly in cellular vulnerability and clinical outcome. We propose that this heterogeneity arises from the interaction between two largely orthogonal variables: the structural identities of protein aggregates and the identities of the cellular proteostasis networks (PNs) that engage them. Protein aggregates exist as structurally diverse assemblies with distinct intrinsic properties. At the same time, PNs vary between cell types, disease states and ageing in their composition, capacity and plasticity. As a result, the same aggregate can be efficiently cleared in one cellular context but persist, be remodelled, or give rise to self-propagating species in another. Likewise, the same PN can be protective or harmful, depending on the aggregate it encounters. Because neither aggregates nor PNs are static, their interaction evolves over time, leading to dynamic feedback between aggregate identity and PN state that shapes disease onset, progression and clinical symptoms. This view reframes neurodegenerative disease as a failure of compatibility between specific aggregate structures and the cellular protein quality control network that processes them rather than as a uniform collapse of proteostasis, and provides a framework for understanding selective vulnerability and disease trajectories. This article is part of the Theo Murphy meeting issue 'ProteostaSys: a systems view of proteostasis'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.